Crossref
Influenza Vaccine for 2023-2024
The Medical Letter on Drugs and Therapeutics · 2023
DOI: 10.58347/tml.2023.1687a ↗Kurz gefasst
Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2023. Hauptthemen laut MEDLINE: Influenza Vaccines, Influenza, Human.
Abstract (Originalsprache)
Annual vaccination in the US against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication.1,2 Influenza vaccines that are available in the US for the 2023-2024 season are listed in Table 2.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Influenza VaccinesInfluenza, HumanHumansAntiviral AgentsOseltamivirNeuraminidaseEnzyme Inhibitors
Stichwörter der Autor:innen
AfluriaFluLavalFluMistFluadFluarixFlublokFluceIvaxFluzoneFluzone High-DoseHeplisav-BRapivabRelenzaShingrixTamifluXofluza
Substanzen
Influenza VaccinesAntiviral AgentsOseltamivirNeuraminidaseEnzyme Inhibitors
Zitieren
APA
(2023). Influenza Vaccine for 2023-2024. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2023.1687a
Vancouver
Influenza Vaccine for 2023-2024. The Medical Letter on Drugs and Therapeutics. 2023. doi:10.58347/tml.2023.1687a
BibTeX
@article{euvimed2023,
title = {Influenza Vaccine for 2023-2024},
journal = {The Medical Letter on Drugs and Therapeutics},
year = {2023},
doi = {10.58347/tml.2023.1687a}
}
EUVIMED